MBX Biosciences, Inc.(MBX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MBX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for MBX Biosciences, Inc. (MBX), a Healthcare sector company. MBX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), MBX Biosciences, Inc. reports net income of $-23.5M, free cash flow of $-20.6M. Top institutional holders of MBX by reported 13-F value include Frazier Life Sciences Management, L.P., ORBIMED ADVISORS, NEA Management Company,, based on the most recent SEC filings. MBX trades on the Nasdaq exchange and files with the SEC under CIK 1776111. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MBX Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-23.5M
Free Cash Flow
Q1 2026
$-20.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-90.1% YoYOperating Income
-93.1% YoYEPS (Diluted)
+81.8% YoYTotal Assets
+219.0% YoYOp. Cash Flow
-71.0% YoY| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Net Income | $-61.9M -90.1% | $-32.6M |
| Operating Income | $-68.2M -93.1% | $-35.3M |
| EPS (Diluted) | $-5.82 +81.8% | $-31.96 |
| Total Assets | $268.5M +219.0% | $84.2M |
| Operating Cash Flow | $-54.7M -71.0% | $-32.0M |
AI Insight: MBX Financial Trends
MBX maintains consistent quarterly burn rate around $20-25M while equity base strengthened significantly to $438M in Q1 2026.
• Net losses remained relatively stable, ranging from $16M to $24M per quarter over seven quarters.
• Equity increased from $271M in Q3 2024 to $438M in Q1 2026, indicating capital raises.
• Operating cash flow burn averaged $19M per quarter, consistent with operating losses.
⚠ No revenue generation reported across all quarters for this healthcare company.
⚠ Quarterly cash burn sustainability depends on continued equity financing given zero revenue base.
AI Insight: MBX Ratio Trends
MBX showed improving profitability metrics through Q1 2026, with ROE recovering from -40.6% in Q1 2025 to -21.5% in the latest quarter.
• ROE improved significantly from -40.6% in Q1 2025 to -21.5% in Q1 2026, indicating reduced losses relative to equity.
• ROIC strengthened from -45.1% in Q1 2025 to -24.9% in Q1 2026, showing better capital efficiency despite remaining negative.
• ROA followed similar improvement trajectory, rising from -38.8% in Q1 2025 to -20.8% in Q1 2026.
⚠ TTM ROE of -19.8% remains better than latest quarter's -21.5%, suggesting potential quarterly volatility in progress.
⚠ All profitability metrics remain deeply negative despite improvement, indicating continued operational losses.
Get alerted when MBX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MBX Biosciences, Inc. including:
Top Institutional Holders of MBX
Frazier Life Sciences Management, L.P.
$198.6M6,652,013 shORBIMED ADVISORS LLC
$108.6M3,637,887 shNEA Management Company, LLC
$107.9M3,614,486 shWELLINGTON MANAGEMENT GROUP LLP
$95.3M3,191,824 shBlackRock, Inc.
$87.8M2,941,406 shFMR LLC
$87.7M2,936,684 shDeep Track Capital, LP
$82.3M2,757,569 shNVP Associates, LLC
$63.8M2,136,335 shPolar Capital Holdings Plc
$48.4M1,622,186 shBRAIDWELL LP
$44.6M1,492,467 sh
| Fund | Value | Shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | $198.6M | 6,652,013 |
| ORBIMED ADVISORS LLC | $108.6M | 3,637,887 |
| NEA Management Company, LLC | $107.9M | 3,614,486 |
| WELLINGTON MANAGEMENT GROUP LLP | $95.3M | 3,191,824 |
| BlackRock, Inc. | $87.8M | 2,941,406 |
| FMR LLC | $87.7M | 2,936,684 |
| Deep Track Capital, LP | $82.3M | 2,757,569 |
| NVP Associates, LLC | $63.8M | 2,136,335 |
| Polar Capital Holdings Plc | $48.4M | 1,622,186 |
| BRAIDWELL LP | $44.6M | 1,492,467 |
More Healthcare Companies
View all Healthcare →Put MBX on your watchlist
Track score changes the day MBX Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MBX a good stock to buy?
13F Pro's AI-powered analysis of MBX Biosciences, Inc. (MBX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MBX are available on the MBX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MBX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MBX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MBX Biosciences, Inc.'s investment landscape.